Bristol: Reduced Rate of Lung Function Decline in Progressive Pulmonary Fibrosis Cohort of Phase 2

 

• Results show 26 weeks of treatment with twice-daily 60 mg dose of BMS-986278 resulted in a 69% relative reduction in the rate of decline in percent predicted forced vital capacity versus placebo
• Treatment effect was consistent with or without background therapy and BMS-986278 was well tolerated, with rates of adverse events similar to placebo and low discontinuation rates
• These progressive pulmonary fibrosis findings, along with the previously reported idiopathic pulmonary fibrosis cohort results, support continued development of BMS-986278 in Phase 3 ALOFT program

https://www.biospace.com/article/releases/bristol-myers-squibb-s-investigational-lpa1-antagonist-reduces-rate-of-lung-function-decline-in-progressive-pulmonary-fibrosis-cohort-of-phase-2-study/